COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

By Ugur Sahin, A. Muik, E. Derhovanessian, I. Vogler, L. Kranz, M. Vormehr, A. Baum, Kristen E. Pascal, Jasmin Quandt, D. Maurus and 32 more. Nature, 2020

1,578 citations recorded by the source corpus.

Subfields: Immunology, Infectious Diseases, Oncology

View Paper: https://www.semanticscholar.org/paper/1d7ade5a3a5fea015a15a083db178101a94e200b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Alessandro Sette
2. Shane Crotty

In Infectious Diseases

1. Alessandro Sette
2. Shane Crotty

In Oncology

1. Shane Crotty

Citations in the corpus

• Adaptive immunity to SARS-CoV-2 and COVID-19 (2021, positive): “T cell data were not reported for BNT162b2, but phase 1 trial data for the related vaccine BNT162b1 (encoding only the Spike RBD domain instead of full-length Spike) showed robust CD4 T cell and CD8 T cell responses, with the CD4 T cell response largely consisting of Th1 cells (Sahin et al., 2020).”